VABu drug combination before stem cell transplant for AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new combination of chemotherapy drugs (called VABu) used before a stem cell transplant to prepare your body. The goal is to see if it is safe and effective for people with AML in first remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have acute myeloid leukemia (AML), but not the APL subtype, and you are in first complete remission after chemotherapy.
- Your leukemia is not classified as high-risk according to the ELN 2022 risk guidelines.
- You have some health challenges (like reduced performance status or other medical conditions), but not severe organ failure.
- You are willing to undergo a stem cell transplant and have a suitable donor.
- You agree to participate after understanding the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy regimen (VABu) combined with a stem-cell transplant for older adults (60+) with acute myeloid leukemia (a blood cancer) who previously responded well to Venetoclax-based treatment. The goal is to see if this approach improves outcomes after transplant.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial studies a combination of two medicines (venetoclax and azacitidine) as a bridge to a stem cell transplant for people with a hard-to-treat type of AML (like secondary AML or with low bone marrow cells). The goal is to get the leukemia under control so a transplant can be done successfully.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests a combination of three drugs (VAH) as a 'bridge' to prepare patients with acute myeloid leukemia (AML) that has come back or not responded to standard treatment for a stem cell transplant. The goal is to see if VAH can help achieve remission and improve transplant outcomes.
This trial tests a combination of two drugs (SHR2554 and azacitidine) given before a stem cell transplant for people with high-risk or relapsed leukemia or MDS. The goal is to see if this approach can help make the transplant more effective and reduce the chance of the disease coming back.
Hear when a new Leukemia, Myeloid, Acute(AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.